130 related articles for article (PubMed ID: 26921394)
1. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.
Liu Z; Yokoyama NN; Blair CA; Li X; Avizonis D; Wu XR; Uchio E; Youssef R; McClelland M; Pollak M; Zi X
Mol Cancer Ther; 2016 Mar; 15(3):430-8. PubMed ID: 26921394
[TBL] [Abstract][Full Text] [Related]
2. AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27.
Kopsiaftis S; Sullivan KL; Garg I; Taylor JA; Claffey KP
Mol Cancer Res; 2016 Dec; 14(12):1182-1194. PubMed ID: 27638620
[TBL] [Abstract][Full Text] [Related]
3. Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer.
Yuge K; Kikuchi E; Hagiwara M; Yasumizu Y; Tanaka N; Kosaka T; Miyajima A; Oya M
Mol Cancer Ther; 2015 Sep; 14(9):2112-20. PubMed ID: 26184482
[TBL] [Abstract][Full Text] [Related]
4. Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.
Liu Z; Song L; Xie J; Wu XR; Gin GE; Wang B; Uchio E; Zi X
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838656
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.
Mo L; Zheng X; Huang HY; Shapiro E; Lepor H; Cordon-Cardo C; Sun TT; Wu XR
J Clin Invest; 2007 Feb; 117(2):314-25. PubMed ID: 17256055
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior.
Garcia-España A; Salazar E; Sun TT; Wu XR; Pellicer A
Cancer Res; 2005 Feb; 65(4):1150-7. PubMed ID: 15734997
[TBL] [Abstract][Full Text] [Related]
7. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.
Zhang T; Guo P; Zhang Y; Xiong H; Yu X; Xu S; Wang X; He D; Jin X
Int J Mol Sci; 2013 Dec; 14(12):24603-18. PubMed ID: 24351837
[TBL] [Abstract][Full Text] [Related]
8. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.
Tang Y; Simoneau AR; Xie J; Shahandeh B; Zi X
Cancer Prev Res (Phila); 2008 Nov; 1(6):439-51. PubMed ID: 19138991
[TBL] [Abstract][Full Text] [Related]
9. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
[TBL] [Abstract][Full Text] [Related]
10. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer.
Jordan AR; Lokeshwar SD; Lopez LE; Hennig M; Chipollini J; Yates T; Hupe MC; Merseburger AS; Shiedlin A; Cerwinka WH; Liu K; Lokeshwar VB
Oncotarget; 2017 Apr; 8(15):24262-24274. PubMed ID: 27419371
[TBL] [Abstract][Full Text] [Related]
12. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.
Gao J; Huang HY; Pak J; Cheng J; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Oncogene; 2004 Jan; 23(3):687-96. PubMed ID: 14737103
[TBL] [Abstract][Full Text] [Related]
13. Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.
Pan Q; Yang GL; Yang JH; Lin SL; Liu N; Liu SS; Liu MY; Zhang LH; Huang YR; Shen RL; Liu Q; Gao JX; Bo JJ
J Exp Clin Cancer Res; 2015 Aug; 34(1):77. PubMed ID: 26245871
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
Buckley MT; Yoon J; Yee H; Chiriboga L; Liebes L; Ara G; Qian X; Bajorin DF; Sun TT; Wu XR; Osman I
J Transl Med; 2007 Oct; 5():49. PubMed ID: 17935615
[TBL] [Abstract][Full Text] [Related]
15. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
16. Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway.
Iida K; Naiki T; Naiki-Ito A; Suzuki S; Kato H; Nozaki S; Nagai T; Etani T; Nagayasu Y; Ando R; Kawai N; Yasui T; Takahashi S
Cancer Sci; 2020 Apr; 111(4):1165-1179. PubMed ID: 31994822
[TBL] [Abstract][Full Text] [Related]
17. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Iglesias DA; Yates MS; van der Hoeven D; Rodkey TL; Zhang Q; Co NN; Burzawa J; Chigurupati S; Celestino J; Bowser J; Broaddus R; Hancock JF; Schmandt R; Lu KH
Mol Cancer Ther; 2013 Dec; 12(12):2847-56. PubMed ID: 24077915
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
[TBL] [Abstract][Full Text] [Related]
19. 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.
Konstantakou EG; Voutsinas GE; Velentzas AD; Basogianni AS; Paronis E; Balafas E; Kostomitsopoulos N; Syrigos KN; Anastasiadou E; Stravopodis DJ
Mol Cancer; 2015 Jul; 14():135. PubMed ID: 26198749
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
